- Home
- LIQT vs MTVA Comparison
LIQT vs MTVA Comparison
Compare LIQT & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIQT
- MTVA
- Stock Information
- Founded
- LIQT 2004
- MTVA 2014
- Country
- LIQT Denmark
- MTVA United States
- Employees
- LIQT N/A
- MTVA N/A
- Industry
- LIQT Industrial Machinery/Components
- MTVA
- Sector
- LIQT Technology
- MTVA
- Exchange
- LIQT Nasdaq
- MTVA NYSE
- Market Cap
- LIQT 18.4M
- MTVA 18.9M
- IPO Year
- LIQT N/A
- MTVA N/A
- Fundamental
- Price
- LIQT $1.83
- MTVA $1.85
- Analyst Decision
- LIQT Strong Buy
- MTVA
- Analyst Count
- LIQT 2
- MTVA 0
- Target Price
- LIQT $4.60
- MTVA N/A
- AVG Volume (30 Days)
- LIQT 37.3K
- MTVA 256.5K
- Earning Date
- LIQT 11-14-2024
- MTVA 11-07-2024
- Dividend Yield
- LIQT N/A
- MTVA N/A
- EPS Growth
- LIQT N/A
- MTVA N/A
- EPS
- LIQT N/A
- MTVA N/A
- Revenue
- LIQT $15,128,295.00
- MTVA N/A
- Revenue This Year
- LIQT N/A
- MTVA N/A
- Revenue Next Year
- LIQT $23.87
- MTVA N/A
- P/E Ratio
- LIQT N/A
- MTVA N/A
- Revenue Growth
- LIQT N/A
- MTVA N/A
- 52 Week Low
- LIQT $1.51
- MTVA $1.55
- 52 Week High
- LIQT $3.61
- MTVA $6.75
- Technical
- Relative Strength Index (RSI)
- LIQT 44.47
- MTVA N/A
- Support Level
- LIQT $1.88
- MTVA N/A
- Resistance Level
- LIQT $2.10
- MTVA N/A
- Average True Range (ATR)
- LIQT 0.14
- MTVA 0.00
- MACD
- LIQT 0.00
- MTVA 0.00
- Stochastic Oscillator
- LIQT 15.91
- MTVA 0.00
About LIQT LiqTech International Inc.
LiqTech International Inc is a clean technology company which provides technology for gas and liquid purification by manufacturing ceramic silicon carbide filters. The company is engaged in three businesses that are diesel particulate filters (DPF) for the control of soot from diesel engines, turnkey ceramic membranes systems, and complete water treatment plants. The company's product portfolio consists of ceramic silicon membranes for liquid filtration, diesel particulate filters, and kiln furniture. Its operating segment includes Water, Ceramics, and Plastics.
About MTVA METAVIA INC
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.